Mueller Ivo, Shakri Ahmad Rushdi, Chitnis Chetan E
Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; Institute of Global Health (ISGLOBAL), Barcelona, Spain.
International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.
Vaccine. 2015 Dec 22;33(52):7489-95. doi: 10.1016/j.vaccine.2015.09.060. Epub 2015 Oct 1.
Plasmodium vivax continues to cause significant morbidity outside Africa with more than 50% of malaria cases in many parts of South and South-east Asia, Pacific islands, Central and South America being attributed to P. vivax infections. The unique biology of P. vivax, including its ability to form latent hypnozoites that emerge months to years later to cause blood stage infections, early appearance of gametocytes before clinical symptoms are apparent and a shorter development cycle in the vector makes elimination of P. vivax using standard control tools difficult. The availability of an effective vaccine that provides protection and prevents transmission would be a valuable tool in efforts to eliminate P. vivax. Here, we review the latest developments related to P. vivax malaria vaccines and discuss the challenges as well as directions toward the goal of developing highly efficacious vaccines against P. vivax malaria.
间日疟原虫在非洲以外地区仍导致大量发病，在南亚、东南亚、太平洋岛屿、中美洲和南美洲的许多地区，超过50%的疟疾病例归因于间日疟原虫感染。间日疟原虫独特的生物学特性，包括其形成潜伏性休眠子的能力（这些休眠子数月至数年后出现导致血液阶段感染）、在临床症状出现之前配子体的早期出现以及在媒介中的发育周期较短，使得使用标准控制工具消除间日疟原虫变得困难。一种能提供保护并预防传播的有效疫苗，将是消除间日疟原虫努力中的一项宝贵工具。在此，我们综述了与间日疟原虫疟疾疫苗相关的最新进展，并讨论了开发高效间日疟原虫疟疾疫苗目标所面临的挑战及方向。
